Olorunseun Ogunwobi

Dr. Olorunseun Ogunwobi obtained a medical degree from the University of Ibadan, Nigeria, a master's degree in biomedicine from the University of Hull, United Kingdom, a master's degree in clinical and translational science from the University of Florida, Gainesville, USA, and a PhD in molecular medicine from the University of East Anglia, Norwich, United Kingdom. He is the founding Director of the Hunter College Center for Cancer Health Disparities Research, Associate Professor of Biological Sciences at Hunter College of The City University of New York, and a member of faculty in the Biology and Biochemistry Ph.D. programs at The Graduate Center of The City University of New York. Dr. Ogunwobi is a Contact Principal Investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by a U54 grant from the National Cancer Institute.

Awards and Grants

Dr. Ogunwobi is the Contact Principal Investigator of National Cancer Institute grant # U54CA221704, grant # 3U54CA221704-03S1, and a Co-Investigator on National Cancer Institute grant # R01CA239603. He was awarded the Carnegie African Diaspora Fellowship by the Carnegie Corporation of New York / Institute of International Education in 2017, and the Minority-Serving Institution Faculty Scholar award by the American Association for Cancer Research in 2014, 2015, and 2016.

Professional Affiliations and Memberships

• Associate Editor in Cancer Genetics, Frontiers in Genetics
• Associate Editor in Cancer Genetics, Frontiers in Oncology
• Associate Editor, PLoS ONE
• Member, American Association for Cancer Research

Courses Taught

BIOL 47117: Clinical Trials
BIOL 35000: Biology of Cancer
BIOL 47130: Biology of Cancer Progression

Publications

• Ogunwobi OO, Segura MF. Editorial: PVT1 in cancer. Front. Oncol. 2020, 10: 588786; doi: 10.3389/fonc.2020.588786.
• Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: Current Research and Future Prospects. Int. J. Mol. Sci. 2020, 21(15), 5311; https://doi.org/10.3390/ijms21155311.
• Huaman J, Ogunwobi OO. Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. Cells 2020, 9(7), 1594; https://doi.org/10.3390/cells9071594.
• Pal G, Di L, Orunmuyi A, Olapade-Olaopa EO, Qiu W, Ogunwobi OO. Population Differentiation at the PVT1 Gene Locus: Implications for Prostate Cancer. G3: Genes, Genomes, Genetics, 2020; 10 (7): 2257-2264.
• Onagoruwa OT, Pal G, Ochu C, Ogunwobi OO. Oncogenic Role of PVT1 and Therapeutic Implications. Front. Oncol. 2020, 10:17, doi: 10.3389/fonc.2020.00017.
• Alegbeleye BJ, Ogunwobi OO. Primary Diffuse Large B-Cell Lymphoma of the Breast: A Rare Case Report and Review of the Literature. International Journal of Scientific Advances. 2020, 1 (2): 79-86.
• T.I. Shireman, A.C. Adia, Y. Tan, L. Zhu, J. Rhee, O.O. Ogunwobi, G.X. Ma, Online Versus In-Person Training of Community Health Workers to Enhance Hepatitis B Virus Screening Among Korean Americans: Evaluating Cost & Outcomes, Preventive Medicine Reports (2020), doi: https://doi.org/10.1016/j.pmedr.2020.101131.
• Pal G, Ogunwobi OO. Copy number - based quantification assay for non - invasive detection of PVT1 - derived transcripts. PLoS ONE. 2019, 14(12): e0226620. https://doi.org/10.1371/journal.pone.0226620.
• Pal G, Huaman J, Levine F, Orunmuyi AT, Olapade-Olaopa EO, Onagoruwa OT, Ogunwobi OO. Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells. Genes. 2019, 10(12), 964; https://doi.org/10.3390/genes10120964.
• Harricharran T, Ogunwobi OO. Oxytocin and oxytocin receptor alterations decreased survival and increased chemoresistance in patients with pancreatic cancer. Hepatobiliary & Pancreatic Diseases International. 2020, DOI: 10.1016/j.hbpd.2019.12.002.
• Anand P, Filipenko P, Huaman J, Lyudmer M, Hossain M, Santamaria C, Huang K, Ogunwobi OO, Holford M. Selective inhibition of liver cancer cells using venom peptide. Marine Drugs. 2019, 17(10), 587; https://doi.org/10.3390/md17100587.
• Zambrano C, Johnson C, Lu W, Beeber M, Panitz A, Wyka K, Ibrahim S, Fraser M, Bhimla A, Tan Y, Navder K, Yeh M, Ma GX, Ogunwobi OO. Dietary behavior and urinary gallic acid concentrations in older minority residents of East Harlem, New York City. Journal of Racial and Ethnic Health Disparities. 2020, 7, 217–223; DOI: 10.1007/s40615-019-00649-x.
• Agrawal R, Chen M, Ogunwobi OO, Bukhari Z, Haseeb MA, Martello LA. EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation In Vitro. Ann. Clin. Lab. Sci. 2020; 50(1):45–56.
• Harricharran T, Ogunwobi OO. Emergence of neural regulatory mechanisms in carcinogenesis. World Journal of Clinical Oncology. 2019; 10 (8): 279-282.
• Ogunwobi OO, Kumar A. Chemoresistance Mediated by ceRNA Networks Associated with the PVT1 Locus. Front Oncol 2019, 9: 834; doi: 10.3389/fonc.2019.00834.
• Harricharran T, Ogunwobi OO. Oxytocin receptor genetic alterations in hepatocellular carcinoma. Springer Nature Comprehensive Clinical Medicine. 2019, 1(7), 523-526; doi: 10.1007/s42399-019-00085-2.
• Huaman J, Naidoo M, Zang X, Ogunwobi OO. Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. Cells 2019, 8, 618.
• Derderian C, Orunmuyi AT, Olapade-Olaopa EO, Ogunwobi OO. PVT1 signaling is a mediator of cancer progression. Front. Oncol. 2019; 9: 502.
• Halpern, M. T., Dodd, SJ, Fang, C. Y., Tan, Y., Zhu, L., Ogunwobi, O. O. & Ma, G. X. Evaluation of a transdisciplinary cancer research training program for under-represented minority students. Informing Science Institute. 2019:99 -108; https://doi.org/10.28945/4343..
• Ogunwobi OO, Ma GX. SPEECH: Synergistic Partnership for Enhancing Equity in Cancer Health. Cancer Health Disparities 2020; doi:10.9777/chd.2019.1012.
• Ogunwobi OO, Dibba O, Zhu L, Ilboudo A, Tan Y, Fraser MA, Ma GX. Hepatitis B Virus Screening and Vaccination in First-Generation African Immigrants: A Pilot Study. Journal of Community Health 2019; 44 (6) 1037–1043; https://doi.org/10.1007/s10900-019-00668-z.
• Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25(19): 2279-2293.
• Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Context Dependent Roles of MDMX (MDM4) and MDM2 in Breast Cancer Proliferation and Circulating Tumor Cells. Breast Cancer Research 2019; 21 (1): 5.
• Lerman B, Harricharran T, Ogunwobi OO. Oxytocin and cancer: An emerging link. World J Clin Oncol 2018; 9(5): 74-82.
• Lee M, Zhu L, Wang MQ, Wei Z, Tan Y, Nguyen MT, Ogunwobi OO, Ma GX. Psychosocial Predictors of HBV Screening Behavior among Vietnamese Americans. Am J Health Behav. 2017 Sep 1;41(5):561-570. doi: 10.5993/AJHB.41.5.5.
• Luu HN, Lin H, Sørensen K, Ogunwobi OO, Kumar N, Chornokur G, Phelan CM, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park J, Di Pietro G. miRNAs associated with Prostate Cancer risk and progression. BMC Urology 2017;17(1):18. doi: 10.1186/s12894-017-0206-6.
• Das DK, Ogunwobi OO. A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer. RNA and Disease 2017; 4: e1503. doi: 10.14800/rd.1503.
• Das DK, Ali T, Krampis K, Ogunwobi OO. Fibronectin and androgen receptor expression data in prostate cancer obtained from a RNA-sequencing bioinformatics analysis. Data in Brief, 2017, 11:131-135.
• Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, Osborne JR, Ogunwobi OO. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Experimental Cell Research. 2016; 348(2):190-200.
• Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016; 2(8):1070-4.
• Das DK, Osborne JR, Park JY, Ogunwobi OO. miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. Translational Oncology. 2016; 9(3): 236–241.
• Ilboudo A, Chouhan J, McNeil BK, Osborne JR, Ogunwobi OO. PVT1 exon 9: a potential biomarker of aggressive prostate cancer? Int. J. Environ Res Public Health, 2016, 13(1), 12; doi:10.3390/ijerph13010012.
• Das DK, Durojaiye V, Ilboudo A, Naidoo MK, Ogunwobi OO. A "patient-like" orthotopic syngeneic mouse model of hepatocellular carcinoma metastasis. J Vis Exp, 2015; (104), e52858, doi:10.3791/52858.
• Das DK, Naidoo MK, Ilboudo A, DuBois P, Durojaiye V, Liu C, Ogunwobi OO. Isolation and propagation of circulating tumor cells from a mouse cancer model. J Vis Exp, 2015; (104), e52861, doi: 10.3791/52861.
• George TJ, Ogunwobi OO, Sheng W, Fan ZH, Liu C. “Tissue is the issue”: circulating tumor cells in pancreatic cancer. Journal of Gastrointestinal Cancer, 2014;45:222-225.
• Sheng W, Ogunwobi OO, Chen T, Zhang J, George TJ, Liu C, Fan ZH. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip, 2014;14(1):89-98.
• Beales IL, Garcia-Morales C, Ogunwobi OO, Mutungi G. Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol, 2014, 382 (1): 150-158.
• Ogunwobi OO, Puszyk W, Dong H, Liu C. Epigenetic upregulation of c-Met and HGF drives metastasis in hepatocellular carcinoma. PLoS One, 2013, 8(5): e63765.
• Zhao X, Tian C, Puszyk W, Ogunwobi OO, Cao M, Wang T, Cabrera R, Nelson D, Liu C. OPA1 down-regulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Laboratory Investigation, 2013, 93(1):8-19.
• Ogunwobi OO, Liu C. Therapeutic and prognostic importance of epithelial-mesenchymal transition in liver cancers: Insights from experimental models. Crit Rev Oncol Hematol, 2012, 83(3):319-28.
• Ogunwobi OO, Wang T, Zhang L, Liu C. COX-2 and Akt mediate multiple growth factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol, 2012, 27 (3): 566-578 (Editorial on pages 418-420).
• Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis, 2011, 28 (8): 721-31.
• Zhao X, Ogunwobi OO, Liu C. Survivin inhibition is critical for bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PLoS One, 2011, 6 (8): e21980.
• Sirica AE, Dumur CI, Campbell DJ, Almenara JA, Ogunwobi OO, Dewitt JL. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol and Hepatol, 2009, 7 (11 Suppl): S68-78.
• Beales ILP, Ogunwobi OO. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in esophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int J Cancer, 2010, 126 (9) 2247-55.
• Beales I, Ogunwobi O. Glycine-extended gastrin inhibits apoptosis in Barrett’s oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation. J Mol Endocrinol, 2009, 42 (4): 305-18.
• Ogunwobi OO, Beales ILP. Statins inhibit proliferation and induce apoptosis in Barrett’s oesophageal adenocarcinoma cells. Am J Gastroenterol, 2008, 103 (4): 825-837 (Editorial on pages 838-41).
• Ogunwobi OO, Beales ILP. Glycine-extended gastrin stimulates proliferation via JAK2- and Akt-dependent NF-KB activation in Barrett's oesophageal adenocarcinoma cells. Mol Cell Endocrinol, 2008, 296 (1-2): 94-102.
• Ogunwobi OO, Beales ILP. Leptin stimulates proliferation of oesophageal adenocarcinoma cells via upregulation of epidermal growth factor receptor ligands. Br J Biomed Sci, 2008, 65 (3): 121-7.
• Ogunwobi OO, Beales ILP. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol, 2008, 285 (1-2): 43-50.
• Ogunwobi O, Mutungi G, Beales ILP. Leptin stimulates proliferation and inhibits apoptosis in Barrett’s oesophageal adenocarcinoma cells by COX-2 dependent, PGE2 mediated transactivation of the EGF receptor and JNK activation. Endocrinology, 2006, 147(9): 4505-4516.
• Ogunwobi OO, Beales ILP. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3-kinase/Akt. Int J Colorectal Dis, 2007, 22 (4): 401–409.
• Ogunwobi OO, Beales ILP. Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells. Dig Dis Sci, 2007 52 (8): 1934-1945.
• Ogunwobi OO, Beales ILP. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol, 2007, 274 (1-2): 60-68.
• Beales ILP, Ogunwobi OO, Cameron E, El-Amin K, Mutungi G and Wilkinson M. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a functional and immunohistochemical study. BMC Cancer, 2007, 7: 97.
• Ogunwobi OO, Beales ILP. The role of adiponectin in colitis. Gastroenterology, 2007, 132 (3): 1199-1200.
• Beales ILP, Ogunwobi O. Glycine-extended gastrin inhibits apoptosis in colon cancer cells via separate activation of Akt and JNK pathways. Mol Cell Endocrinol, 2006, 247 (1-2): 140-149.
• Ogunwobi OO, Beales ILP. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006 134 (2-3): 105-113.
• Ogunwobi OO, Beales ILP. Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase independent pathways. Regul Pept, 2006, 134 (1): 1-8.
• Beales ILP, Ogunwobi O. Adipokines and gastrointestinal disease. Aliment Pharmacol Ther, 2006, 24: 1127.